{"id":"hrs-1780-tablets","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available regarding the specific molecular mechanism of HRS-1780. As a Phase 3 candidate from Shandong Suncadia Medicine Co., Ltd., the drug is in late-stage clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.","oneSentence":"HRS-1780 is an investigational small molecule with unknown mechanism of action in Phase 3 development.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:02.770Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07419828","phase":"PHASE3","title":"A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-13","conditions":"Chronic Kidney Disease","enrollment":1978},{"nctId":"NCT07470983","phase":"PHASE2","title":"A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03","conditions":"Primary Aldosteronism","enrollment":60},{"nctId":"NCT06221059","phase":"PHASE2","title":"Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-03-02","conditions":"Chronic Kidney Disease","enrollment":181},{"nctId":"NCT06495931","phase":"PHASE1","title":"Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-07","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT06344936","phase":"PHASE1","title":"Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-04","conditions":"Chronic Kidney Disease(CKD)","enrollment":28},{"nctId":"NCT05638126","phase":"PHASE1","title":"Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects","status":"UNKNOWN","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2023-02-02","conditions":"Chronic Kidney Disease","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HRS-1780 Tablets","genericName":"HRS-1780 Tablets","companyName":"Shandong Suncadia Medicine Co., Ltd.","companyId":"shandong-suncadia-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}